To determine the efficacy of the LPPC-based complexes for drug targeting in vitro, the fluorescence dye DiO labeled-LPPC/Herceptin complexes were first determined their abilities to interact with the various breast cancer cells with different surface expression levels of HER2/neu (Fig. 2a, above panel). Here, ERBB2 is linked to breast carcinoma.